Insights

Every year, dozens of pharmaceutical patents expire quietly. A few dozen more get abandoned before they even reach their full […]

The pharmaceutical industry is trapped in a pincer movement. On one side, the cost of developing a new molecular entity

Introduction: The Graveyard With a Pulse Every year, thousands of pharmaceutical patents die quietly. No press release. No analyst call.

Why CIS Patent Terms Confuse Even Experienced IP Professionals When a pharmaceutical company’s legal team maps out its global IP

Every year, pharmaceutical executives sit in board rooms and learn that a product generating hundreds of millions of dollars in

The Hatch-Waxman Act was never designed to be a gift to branded pharmaceutical companies. Congress passed the Drug Price Competition

This is the arbitrage opportunity. The pharmaceutical secondary market — distressed assets, out-licensed compounds, abandoned pipelines, post-patent small molecules —

The instinct, when a primary patent approaches expiration, is to treat it as a loss event. Revenue projections get marked

The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion